Agenda

 

 

Monday, October 28, 2019

07:30 am - 08:00 am
Check-in for registration
08:00 am - 08:05 am
Welcome Remarks: Tim Greten, M.D., NIH, NCI, CCR
08:05 am - 08:10 am
Opening Remarks: Doug Lowy, M.D., NIH, NCI
08:10 am - 09:00 am
Keynote Lecture: Craig Thompson, M.D., Memorial Sloan Kettering Cancer Center

"The Role of Cancer Cell Metabolism in Shaping the Tumor Microenvironment"

 

Session 1: RISK FACTORS AND METABOLISM

Co-Chairs: Tim Greten, M.D. & Mitchell Ho, Ph.D. 

09:00 am - 09:25 am
Katherine McGlynn, Ph.D., M.P.H., NIH, NCI, DCEG

"Bacterial translocation and risk of liver cancer in two populations"    

09:25 am - 09:50 am
Bin Gao, M.D., Ph.D., NIH, NIAAA

"Alcohol Metabolism, Alcoholic Liver Disease and Cancer"   

09:50 am - 10:15 am
Anna Mae Diehl, M.D., Duke University

"NonAlcoholic Fatty Liver Disease and Liver Cancer" 

10:15 am - 10:30 am
Bernd Heinrich, M.D., NIH, NCI, CCR

“Nonalcoholic fatty liver disease impairs efficacy of T cell-based immunotherapies for liver metastases in mice”

10:30 am - 10:45 am

 

Break

10:45 am - 11:10 am
Jake Liang, M.D., NIH, NIDDK

"Hepatitis C Virus: The Bogeyman, a Metabolic Rubicon and Liver Cancer"

11:10 am - 11:35 am
Anuradha Budhu, Ph.D., NIH, NCI, CCR

"Discerning liver tumor subtypes with altered obesity-related metabolism"

11:35 am - 12:00 pm
Guadalupe Sabio Buzo, Ph.D., Spanish National Center for Cardiovascular Disease

"Liver Stress kinases – crossroad between obesity and liver cancer"  

12:00 pm - 01:00 pm

 

Lunch (on your own)

01:00 pm - 01:10 pm
Melinda Bachini, Cholangiocarcinoma Foundation

 

Session 2: MICROBIOME, IMMUNE BIOLOGY AND METABOLISM 

Co-Chairs: Frank Gonzalez, Ph.D. & Giorgio Trinchieri, M.D.

 

01:10 pm - 01:35 pm
Tim Greten, M.D., NIH, NCI, CCR

"How does the microbiome and fatty liver disease control anti-tumor immunity?"

01:35 pm - 02:00 pm
Theo Heller, M.D., NIH, NCI, CCR

“The missing link? To the portal vein and beyond

02:00 pm - 02:25 pm
Matam Vijay-Kumar, Ph.D., University of Toledo

"Interplay Between Dietary Fiber and Gut Microbiota in Liver Cancer: The Dark Side of Fermentation"

02:25 pm - 02:40 pm
Yong He, Ph.D., NIH, NIAAA

"MicroRNA-223 in nonalcoholic steatohepatitis and cancer"

 

02:40 pm - 03:40 pm

 

Poster Session

03:40 pm - 04:05 pm
Robert Schwabe, M.D., Columbia University

"The commensal gut microbiota restrict metastatic tumor growth in the liver"

04:05 pm - 04:30 pm
Grace Guo, MBBS, Ph.D., Rutgers University

"Role of FGF15 in promoting liver regeneration"

04:30 pm - 04:55 pm
Dan McVicar, Ph.D., NIH, NCI, CCR

"Metabolic Niches in Cancer and Inflammation"

04:55 pm - 05:20 pm
Wanjun Chen, M.D., NIH, NIDCR

"Sugar, Th17 cell and mucosal inflammation"

Tuesday, October 29, 2019

08:00 am - 08:30 am
Check-in for registration

Session 3: GENETICS, GENOMICS and METABOLISM

Co-Chairs: Xin Wang, Ph.D. & Natalie Porat-Shliom, Ph.D. 

08:30 am - 08:55 am
Lars Zender, Prof. Dr.med, University of Tübingen 

"Translating Liver Cancer Biology: From functional Target Discovery to Academic Drug Development"

08:55 am - 09:20 am
Wei Guo, Ph.D., University of Pennsylvania

"The Exosomes in Immune Suppression and Tumor Progression"

09:20 am - 09:45 am
Satdarshan (Paul) S. Monga, M.D., University of Pittsburgh

"Beta-catenin Mutations in Hepatocellular Cancer: Implications in Tumor Metabolism and Therapy"

09:45 am - 10:00 am
Man Hsin Hung, M.D., Ph.D., NIH, NCI, CCR

"Tumor Methionine Metabolism Drives T Cell Dysfunction In Hepatocellular Carcinoma"

10:00 am - 10:15 am

 

Break

10:15 am - 10:30 am
Fuming Li, Ph.D., University of Pennsylvania

"FBP1 as a metabolic tumor suppressor in liver cancer"

10:30 am - 10:55 am
Jessica Zucman-Rossi, M.D., Ph.D., University Paris Descartes

"Natural history of liver tumors revisited by genomics"

10:55 am - 11:20 am
Nabeel Bardeesy, Ph.D., Harvard University

"Preclinical modeling of targeted therapies for cholangiocarcinoma"

11:20 am - 11:45 am
Kevin Brindle, DPhil., University of Cambridge

"Magnetic resonance imaging of tumor metabolism"

11:45 am - 12:00 pm
Closing Remarks: Xin Wang, Ph.D., NIH, NCI, CCR